Market Overview

Cresco Labs' Dispensary Launches Newly Enacted Illinois Opioid Alternative Pilot Program


(CSE:CL) ("Cresco" or "the Company"), one of the largest
vertically integrated multistate cannabis operators in the United
States, announced that the Company's FloraMedex dispensary launched
Illinois' Opioid Alternative Pilot Program (OAPP) today vastly expanding
the population of Illinois patients who can access medical cannabis in
place of pharmaceutical opioid medications. Under this new program,
patients with doctor approval can receive near-immediate access to
cannabis products from an Illinois licensed dispensary. The OAPP
eliminates the previously required red tape – fingerprinting and
background checks – that often delay patients access to medical cannabis
by up to three months. Under this act, Medical Cannabis Pilot Program
(MCPP) patients with one of the 41 qualifying medical conditions
designated by the state of Illinois, and a doctor recommendation can
also receive a temporary medical cannabis card online and make immediate
cannabis purchases without waiting for their permanent card to be

This press release features multimedia. View the full release here:

Illinois alternative to opioid patient Tashena Altman makes first medical cannabis purchase under Il ...

Illinois alternative to opioid patient Tashena Altman makes first medical cannabis purchase under Illinois new law. (Photo: Business Wire)

"The passage of the Opioid Alternative Pilot Program is important
legislation for the patients across Illinois that have been looking for
an alternative form of relief, and we are very excited to make the first
sale of medical cannabis under the program," said Cresco Labs CEO and
co-founder Charles Bachtell. "The program will open up access to medical
cannabis across the state and eliminate the wait time and red tape
previously required. Opioid addiction impacts up to two million citizens
across our country, and we are proud that Cresco Labs is now able to
offer Illinois patients a better treatment option and much-needed

The Alternative to Opioids Act was signed into law by then-Governor
Bruce Rauner in August 2018. The Act significantly expands access to
Illinois' medical cannabis program by allowing patients to purchase
medical cannabis in place of doctor prescribed opioid medications. In
2017 alone, over two million patients received nearly five million
opioid prescriptions in Illinois. Now, under the pilot program, patients
with one of 41 qualifying medical conditions and a doctor's
recommendation can choose cannabis over opioid treatment and receive a
temporary medical cannabis card online. Cannabis purchases can then be
made immediately without waiting for a permanent card to be processed.

About Cresco Labs:

Cresco Labs, based in Chicago, is a leading U.S. cannabis company with
experienced management, access to capital and a demonstrated growth
strategy. As a differentiated grower, processor and retailer of premium
cannabis operating in seven states, the company focuses on entering
highly regulated markets with outsized demand potential and high
barriers to entry. Its impressive speed-to-market gives Cresco a
distinct competitive advantage as it replicates its model to expand its
national footprint. Cresco's proven ability to execute is complemented
by a cutting-edge brand strategy spearheaded by several of the brightest
minds in consumer marketing in the nation. Cresco's products are
tailored to all major consumer segments: everyday cannabis, medicinally
focused, connoisseur grade, and chef-inspired edibles by James Beard
Award-winning pastry chef Mindy Segal. Learn more about Cresco Labs at

Forward Looking Statements

This press release contains "forward-looking information" within the
meaning of applicable Canadian securities legislation and may also
contain statements that may constitute "forward-looking statements"
within the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Such forward-looking
information and forward-looking statements are not representative of
historical facts or information or current condition, but instead
represent only the Company's beliefs regarding future events, plans or
objectives, many of which, by their nature, are inherently uncertain and
outside of the Company's control. Generally, such forward-looking
information or forward-looking statements can be identified by the use
of forward-looking terminology such as, ‘may,' ‘will,' ‘should,'
‘could,' ‘would,' ‘expects,' ‘plans,' ‘anticipates,' ‘believes,'
‘estimates,' ‘projects,' ‘predicts,' ‘potential' or ‘continue' or the
negative of those forms or other comparable terms. The Company's
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the Company's actual
results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the
forward-looking statements, including but not limited to those risks
discussed under "Risk Factors" in the company's CSE Listing Statement
filed with SEDAR; and other factors, many of which are beyond the
control of the Company. Readers are cautioned that the foregoing list of
factors is not exhaustive. Because of these uncertainties, you should
not place undue reliance on the Company's forward-looking statements. No
assurances are given as to the future trading price or trading volumes
of Cresco's shares, nor as to the Company's financial performance in
future financial periods. The Company does not intend to update any of
these factors or to publicly announce the result of any revisions to any
of the Company's forward-looking statements contained herein, whether as
a result of new information, any future event or otherwise. Except as
otherwise indicated, this press release speaks as of the date hereof.
The distribution of this press release does not imply that there has
been no change in the affairs of the Company after the date hereof or
create any duty or commitment to update or supplement any information
provided in this press release or otherwise.

View Comments and Join the Discussion!